ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-PD-1/IL-15 Fusion Protein JMT108

Also written as “JMT108”, “SYS6090 Injection + Bevacizumab Injection” and “SYS6090 Injection +SYS6043 Injection +Bevacizumab Injection”.

Its studies are mostly in Melanoma · Carcinoma, Hepatocellular · Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Neoplasms, led by 2 companies.

Drug pageAnti-PD-1/IL-15 Fusion Protein JMT108: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Mar 6, 20256 company-led studies, 6 open or runningNext primary completion: Nov 30, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSPC Pharmaceutical Groupits history only55 open or runningphase 2since Mar 6, 2025Mar 6, 2025Nov 30, 2026phase 2 · NCT07280832
Conjupro Biotherapeuticsits history only11 open or runningphase 1since Nov 25, 2025Nov 25, 2025Jul 2029phase 1 · NCT07317505

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 6, 2025First study: phase 2 study in Advanced Malignant TumorsNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT06877650 · 436 planned · China
  2. Nov 25, 2025Conjupro Biotherapeutics’ first study: phase 1 study in NeoplasmsNew to Conjupro BiotherapeuticsConjupro Biotherapeutics · NCT07317505 · 270 planned · United States
  3. Nov 28, 2025Phase 2 study in MelanomaCSPC Pharmaceutical Group · NCT07280832 · 500 planned · China
  4. Feb 4, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungCSPC Pharmaceutical Group · NCT07472647 · 596 planned
  5. Jul 30, 2026Phase 2 study in Carcinoma, HepatocellularCSPC Pharmaceutical Group · NCT07761286 · 288 planned · China
  6. Aug 2, 2026Phase 2 study in Colorectal NeoplasmsCSPC Pharmaceutical Group · NCT07750041 · 260 planned · China

Ahead

  1. Nov 30, 2026Primary completion: phase 2 study in MelanomaCSPC Pharmaceutical Group · NCT07280832
  2. Dec 31, 2027Primary completion: phase 2 study in Colorectal NeoplasmsCSPC Pharmaceutical Group · NCT07750041
  3. Mar 30, 2028Primary completion: phase 2 study in Advanced Malignant TumorsCSPC Pharmaceutical Group · NCT06877650
  4. Feb 28, 2029Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungCSPC Pharmaceutical Group · NCT07472647

TargetBeta

PDCD1 →read by rule
“A recombinant fusion protein composed of an antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) ”NCIt, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07750041Colorectal Neoplasms · China2Not yet recruitingCSPC Pharmaceutical GroupDec 31, 2027260
NCT07761286Carcinoma, Hepatocellular · China2Not yet recruitingCSPC Pharmaceutical GroupSep 30, 2029288
NCT07472647Carcinoma, Non-Small-Cell Lung2Not yet recruitingCSPC Pharmaceutical GroupFeb 28, 2029596
NCT07280832Melanoma · China2RecruitingCSPC Pharmaceutical GroupNov 30, 2026500
NCT07317505Neoplasms · United States1RecruitingConjupro BiotherapeuticsJul 2029270
NCT06877650Advanced Malignant Tumors · China2RecruitingCSPC Pharmaceutical GroupMar 30, 2028436

How it is read

Names in the registry

  • “JMT108”, 3 entries
  • “SYS6090 Injection + Bevacizumab Injection”, 1 entry
  • “SYS6090 Injection +SYS6043 Injection +Bevacizumab Injection”, 1 entry
  • “SYS6090 (Fixed Dose Level A) + bevacizumab”, 1 entry
  • “SYS6090 (Fixed Dose Level B ) + bevacizumab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.